Health Care & Life Sciences » Pharmaceuticals | Guizhou Yibai Pharmaceutical Co. Ltd.

Guizhou Yibai Pharmaceutical Co. Ltd. A | Cash Flow

Fiscal year is January-December. All values CNY Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
431,009.50
481,202.00
191,994.80
393,397.20
407,779.30
684,486.80
Depreciation, Depletion & Amortization
55,235.30
91,318.20
100,403.50
124,967.90
169,252.70
226,535.70
Other Funds
25,437.90
1,030,554.80
128,606.30
70,683.10
120,651.00
1,190,695
Funds from Operations
535,278.00
605,673.40
303,313.50
589,832.70
661,250.10
569,191.90
Changes in Working Capital
41,977.90
63,833.80
220,120.60
209,049.10
20,641.90
354,549.90
Net Operating Cash Flow
577,255.90
541,839.70
523,434.10
380,783.60
681,892.00
214,642
Capital Expenditures
273,483.50
203,935.80
288,017.50
332,533.10
402,797.60
Sale of Fixed Assets & Businesses
30,607.30
74.90
100.70
31,837.60
24,995.60
Purchase/Sale of Investments
500,900.00
635,573.70
630,542.00
40,683.20
54,410.00
Net Investing Cash Flow
734,151.30
788,185.10
935,792.50
547,136.70
414,506.80
Cash Dividends Paid - Total
54,087.70
47,507.40
47,515.60
15,838.50
-
Issuance/Reduction of Debt, Net
92,953.00
205,007.10
292,030.00
297,943.80
86,712.00
Net Financing Cash Flow
13,427.40
1,188,054.50
373,120.60
211,422.20
33,939.00
Net Change in Cash
143,468.00
941,709.00
39,237.80
45,069.20
233,446.20
Free Cash Flow
303,772.40
337,903.90
235,416.60
48,250.50
279,094.40
Deferred Taxes & Investment Tax Credit
8,309.70
1,978.20
1,939.80
3,083.50
3,309.30
163,551.90
Net Assets from Acquisitions
-
-
210.20
195,877.90
17,705.20
Other Sources
9,624.80
80,560.90
-
-
-
Other Uses
-
29,311.40
17,123.40
9,880.00
-

About Guizhou Yibai Pharmaceutical Co.

View Profile
Address
No. 220-1 Baiyun Avenue
Guiyang Guizhou 550008
China
Employees -
Website http://e.gzcci.com
Updated 07/08/2019
Guizhou Yibai Pharmaceutical Co., Ltd. engages in the manufacture and distribution of pharmaceutical products. Its business activities include the production and sale of capsules, small-volume injection, tablet, granules, bran paste agent, freeze-dried powder, oral solution; production and sale of medicine for respiratory disease; and cardiovascular disease prevention and treatment. The company also engages in the export of self-produced products and related technology; import of raw and auxiliary materials; machinery and equipment; spare parts and related technologies as required by company's production and research.